OncoXchange

https://lnkd.in/eHhQ5uVA This session will explore the evolving landscape of HER2+ brain metastases management and address critical challenges in patient care. Don’t miss this opportunity to learn from leading oncologists and participate in a dynamic conversation. Dr. Nancy Lin presents the latest advancements in systemic therapies, with Dr. Katarzyna Jerzak moderating the discussion. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #SABCS2024 #precisionmedicine #oncologist Groupe McPeak-Sirois de recherche clinique en cancer du sein

https://lnkd.in/eAv-cvCv Dr. Paolo Tarantino will share insights into the latest breast cancer consensus guidelines, with a focus on the evolving role of ADCs and how to move beyond guidelines in clinical decision-making. Dr. Nathaniel Bouganim will lead a comparative analysis with Canadian practices, exploring how global recommendations can be adapted to real-world oncology care. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #precisionmedicine #oncologist Groupe McPeak-Sirois de recherche clinique en cancer du sein

https://lnkd.in/dAEgyAyS Dr. Sara Tolaney highlights the PATINA trial's PFS boost with Palbociclib for HER2-positive breast cancer and EMBER-3's findings on Imlunestrant and Abemaciclib for HR+ breast cancer, reshaping metastatic treatment approaches. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #SABCS2024 #precisionmedicine #oncologist Groupe McPeak-Sirois de recherche clinique en cancer du sein

https://lnkd.in/d4wDsv7x Dr. Edith Perez reviews SABCS 2024, highlighting breakthroughs in breast cancer care, collaboration across sectors, and the vital role of training junior investigators to advance research and improve patient outcomes. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #SABCS2024 #precisionmedicine #oncologist Groupe McPeak-Sirois de recherche clinique en cancer du sein

https://lnkd.in/edwYWpMN Dr. Sara Tolaney discusses the TroFuse-010 Trial, a phase 3 study evaluating Sacituzumab and combinations for metastatic HR+ breast cancer post-CDK4/6 inhibition, aiming to compare outcomes with standard chemotherapy. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #SABCS2024 #precisionmedicine #oncologist

https://lnkd.in/exCUfiAx Dr. Andreas Nearchou presents real-world data on the safety and effectiveness of switching among biosimilars for HER2-positive breast cancer, offering insights from his role as principal investigator. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #SABCS2024 #precisionmedicine #oncologist

https://lnkd.in/eQgNfwbs Dr. Virginia Kaklamani discusses pivotal SABCS 2024 trials, including Imlunestrant's superiority, PARP inhibitors' preventive role, PATINA's PFS outcomes, and OlympiA's OS data, reshaping breast cancer care standards. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #SABCS2024 #precisionmedicine #oncologist

https://lnkd.in/eD_gX7jk Dr. Nagi El Saghir, Professor at AUB Medical Center in Beirut, highlights six key abstracts from SABCS 2024. He shares insights on the rich multidisciplinary data presented this year, spanning innovations in breast cancer research and treatment. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #SABCS2024 #precisionmedicine #oncologist

https://lnkd.in/eJsbV4ik Dr. Rita A. Sakr, Head of breast cancer surgery at Emirates Hospital Dubai, discusses breast cancer survivors’ perspectives on de-escalation treatments in the Arab world and emphasizes the importance of education and raising awareness on de-escalation protocols. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #SABCS2024 #precisionmedicine #oncologist

https://lnkd.in/eyBG7Xaj Dr. Antonio Wolff shares expert commentary on SABCS 2024 highlights, including the practice-changing PATINA study, DCIS data, the COMET study, and the FDA's discussion on the importance of ovarian toxicity monitoring during clinical trials. #cancerresearch #breastcancer #breastcancerresearch #oncology #oncologyresearch #oncologytrials #cancertherapy #breastcancertreatment #cancerdusein #clinicaltrials #metastaticbreastcancer #her2 #SABCS2024 #precisionmedicine #oncologist Groupe McPeak-Sirois de recherche clinique en cancer du sein